Stock listing
NASDAQ:BRVE Braveheart Bio, Inc. Stock
Home listing (NASDAQ) of Braveheart Bio, Inc.
Follow Braveheart Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BRVE
$20.39 USD +1.86 (+10.0%)
Close on Nov 20, 2026
- Day range
- $18.83 – $21.11 USDNov 20, 2026
- Volume
- 866,730 sharesNov 20, 2026
- Market cap
- $1.84B USDAt the close on Nov 20, 2026 · price × 90.04M shares outstanding
- Traded on an average day
- $10.60M USDMedian day 342,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BRVE · Home | $20.39 USD | +1.86 (+10.0%) | 866,730 | $19.29 | $21.11 | $18.83 | $18.53 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BRVE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $20.39 | +1.86 | +10.0% | $19.29 | $21.11 | $18.83 | 866,730 | |
| $18.53 | -0.25 | -1.3% | $18.48 | $19.42 | $17.95 | 706,907 | |
| $18.78 | -0.71 | -3.6% | $19.46 | $19.46 | $17.79 | 971,285 | |
| $19.49 | -0.13 | -0.7% | $20.04 | $20.21 | $18.71 | 725,376 | |
| $19.62 | -0.88 | -4.3% | $20.41 | $20.41 | $19.19 | 536,604 | |
| $20.50 | -0.40 | -1.9% | $20.97 | $21.30 | $20.01 | 256,070 | |
| $20.90 | +1.28 | +6.5% | $20.04 | $21.85 | $19.41 | 488,966 | |
| $19.62 | +0.16 | +0.8% | $19.13 | $19.76 | $18.88 | 211,466 | |
| $19.46 | +0.86 | +4.6% | $19.08 | $19.87 | $18.61 | 618,350 | |
| $18.60 | +1.185 | +6.8% | $17.55 | $18.99 | $16.89 | 702,051 | |
| $17.42 | -2.69 | -13.4% | $19.84 | $19.84 | $16.70 | 1,590,097 | |
| $20.11 | -1.285 | -6.0% | $21.54 | $21.56 | $19.16 | 655,535 | |
| $21.39 | +0.35 | +1.7% | $20.94 | $21.53 | $20.24 | 305,539 | |
| $21.04 | -0.47 | -2.2% | $21.79 | $21.79 | $20.51 | 260,119 | |
| $21.51 | +0.32 | +1.5% | $21.29 | $21.77 | $20.75 | 533,666 | |
| $21.19 | -0.57 | -2.6% | $21.55 | $22.20 | $20.62 | 304,125 | |
| $21.76 | -0.06 | -0.3% | $21.74 | $21.85 | $20.77 | 246,219 | |
| $21.82 | -0.05 | -0.2% | $22.00 | $22.22 | $21.38 | 156,109 | |
| $21.87 | +0.43 | +2.0% | $21.71 | $21.96 | $21.32 | 101,220 | |
| $21.44 | -0.04 | -0.2% | $21.45 | $21.53 | $20.58 | 119,555 | |
| $21.48 | +0.44 | +2.1% | $21.14 | $21.80 | $20.68 | 156,502 | |
| $21.04 | +0.77 | +3.8% | $20.64 | $21.36 | $19.67 | 224,146 | |
| $20.27 | +1.06 | +5.5% | $19.21 | $20.81 | $19.15 | 323,870 | |
| $19.21 | +0.50 | +2.7% | $18.72 | $19.42 | $18.15 | 333,743 | |
| $18.71 | -0.84 | -4.3% | $19.50 | $19.59 | $18.00 | 414,900 | |
| $19.55 | +0.21 | +1.1% | $19.54 | $20.13 | $19.18 | 206,100 | |
| $19.34 | +0.01 | +0.1% | $19.33 | $19.90 | $18.62 | 462,800 | |
| $19.33 | -1.03 | -5.1% | $20.44 | $20.56 | $19.04 | 212,300 | |
| $20.36 | +0.34 | +1.7% | $20.17 | $20.78 | $19.22 | 155,100 | |
| $20.02 | +0.93 | +4.9% | $18.91 | $20.24 | $18.44 | 255,000 | |
| $19.09 | +0.51 | +2.7% | $18.53 | $19.32 | $17.86 | 389,200 | |
| $18.58 | -1.21 | -6.1% | $19.61 | $19.65 | $18.47 | 336,900 | |
| $19.79 | -1.56 | -7.3% | $21.59 | $21.59 | $19.67 | 590,300 | |
| $21.35 | +0.08 | +0.4% | $21.57 | $22.02 | $19.83 | 889,000 | |
| $21.27 | -0.14 | -0.7% | $21.44 | $21.98 | $20.77 | 462,800 | |
| $21.41 | +1.21 | +6.0% | $19.90 | $22.36 | $19.88 | 669,400 | |
| $20.20 | -2.14 | -9.6% | $22.30 | $22.30 | $20.01 | 967,500 | |
| $22.34 | +1.27 | +6.0% | $21.00 | $22.51 | $20.37 | 719,200 | |
| $21.07 | +0.45 | +2.2% | $20.25 | $22.05 | $20.01 | 389,300 | |
| $20.62 | -2.75 | -11.8% | $23.58 | $23.86 | $20.53 | 471,800 | |
| $23.37 | +1.91 | +8.9% | $21.41 | $23.80 | $20.70 | 396,700 | |
| $21.46 | -2.15 | -9.1% | $23.21 | $23.77 | $21.31 | 521,700 | |
| $23.61 | -1.41 | -5.6% | $25.41 | $25.41 | $23.42 | 829,400 | |
| $25.02 | -4.18 | -14.3% | $28.90 | $28.90 | $24.63 | 1,570,800 | |
| $29.20 | +1.49 | +5.4% | $27.78 | $29.50 | $27.47 | 2,017,800 | |
| $27.71 | +0.26 | +0.9% | $27.76 | $28.90 | $27.16 | 577,400 | |
| $27.45 | +0.74 | +2.8% | $26.82 | $28.90 | $26.22 | 550,700 | |
| $26.71 | -0.31 | -1.1% | $26.95 | $27.98 | $26.31 | 275,000 | |
| $27.02 | +0.38 | +1.4% | $26.75 | $27.76 | $26.29 | 209,200 | |
| $26.64 | -0.61 | -2.2% | $28.12 | $28.74 | $26.54 | 283,600 | |
| $27.25 | -1.66 | -5.7% | $28.94 | $29.50 | $26.47 | 286,000 | |
| $28.91 | -0.50 | -1.7% | $29.13 | $29.97 | $27.93 | 309,700 | |
| $29.41 | +2.67 | +10.0% | $27.18 | $29.91 | $27.18 | 613,200 | |
| $26.74 | +0.47 | +1.8% | $25.81 | $27.48 | $25.39 | 272,100 | |
| $26.27 | -0.68 | -2.5% | $27.22 | $27.22 | $25.19 | 327,600 | |
| $26.95 | +0.67 | +2.5% | $26.53 | $27.78 | $25.69 | 394,500 | |
| $26.28 | +0.78 | +3.1% | $25.76 | $27.06 | $24.90 | 342,900 | |
| $25.50 | -1.94 | -7.1% | $27.95 | $27.95 | $24.31 | 806,200 | |
| $27.44 | -0.42 | -1.5% | $27.98 | $29.24 | $27.38 | 162,500 | |
| $27.86 | +0.10 | +0.4% | $27.50 | $29.00 | $27.50 | 127,800 | |
| $27.76 | +0.12 | +0.4% | $27.80 | $28.65 | $27.01 | 215,200 | |
| $27.64 | +0.14 | +0.5% | $28.29 | $29.25 | $27.07 | 155,335 | |
| $27.50 | -0.08 | -0.3% | $27.64 | $28.00 | $26.17 | 101,993 | |
| $27.58 | +0.16 | +0.6% | $27.49 | $28.10 | $27.12 | 130,500 | |
| $27.42 | -1.55 | -5.4% | $28.43 | $28.89 | $26.54 | 176,200 |
- Ticker
- NASDAQ:BRVE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · May 11, 2026
Technical Presentation (May 2026)
Technical · 16 slides
Latest news
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 10, 2026
Closed $20.90 (+6.5%) on Nov 11, 2026
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
Nov 9, 2026
Closed $19.46 (+4.6%) on Nov 9, 2026
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
Nov 6, 2026
Closed $18.60 (+6.8%) on Nov 6, 2026
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
Oct 30, 2026
Closed $21.51 (+1.5%) on Oct 30, 2026
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
Oct 30, 2026
Closed $21.51 (+1.5%) on Oct 30, 2026
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
Sep 16, 2026
Closed $27.71 (+0.9%) on Sep 17, 2026
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Sep 8, 2026
Closed $28.91 (-1.7%) on Sep 9, 2026
Braveheart Bio to Participate in Cantor Global Healthcare Conference
Sep 1, 2026
Closed $26.95 (+2.5%) on Sep 2, 2026
Braveheart Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 10 in the last 12 months · 10 in all · newest Nov 10, 2026 · oldest 2026
- Decks
- 2 decks · latest May 11, 2026
Where Braveheart Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BRVE · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BRVE | BOATS | United States | USD |
Valuation
Price/book 3.7× against a median of 4.9×: 2nd lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.71B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Braveheart Bio, Inc. · NASDAQ:BRVE | US$1.84B | US$1.71B | n/a | n/a | n/a | 3.7× | n/a | 0.0× | n/a |
| Shanghai Henlius Biotech, Inc. Class H · HKEX:2696 | US$1.91B | US$2.36B | 14.7× | 2.1× | 12.3× | 2.8× | 11.7% | 0.9× | n/a |
| Trevi Therapeutics, Inc. · NASDAQ:TRVI | US$1.90B | US$1.60B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.22 |
| Biohaven Ltd. · NYSE:BHVN | US$1.87B | US$1.71B | n/a | n/a | n/a | n/a | n/a | n/a | 1.19 |
| BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRX | US$1.86B | US$1.88B | n/a | 1.9× | n/a | n/a | −37.4% | n/a | 0.62 |
| Immunome, Inc. · NASDAQ:IMNM | US$1.85B | US$1.40B | n/a | n/a | n/a | 4.1× | n/a | 0.0× | 1.49 |
| Zymeworks Inc. · NASDAQ:ZYME | US$1.84B | US$2.08B | 42.5× | 7.8× | 40.6× | 7.1× | 16.3% | 1.3× | 0.69 |
| Vera Therapeutics, Inc. · NASDAQ:VERA | US$1.84B | US$1.53B | n/a | 149× | n/a | 5.5× | n/a | 0.2× | 1.13 |
| Hemab Therapeutics Holdings, Inc. · NASDAQ:COAG | US$1.84B | US$1.41B | n/a | n/a | n/a | 4.3× | n/a | 0.0× | 0.61 |
| Septerna, Inc. · NASDAQ:SEPN | US$1.84B | US$1.38B | n/a | 14.3× | n/a | 4.3× | −61.3% | 0.1× | 0.95 |
| Replimune Group, Inc. · NASDAQ:REPL | US$1.81B | US$1.60B | n/a | n/a | n/a | 8.8× | n/a | 0.5× | 0.78 |
| Median of the others | US$1.85B | US$1.60B | 28.6× | 7.8× | 26.5× | 4.9× | −12.9% | 0.1× | 0.95 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 45.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.82 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Travis Murdoch | Chief Executive Officer and Board Director |
| Paul Rickey | Chief Financial Officer |
| Brittany de Temple | Senior Vice President, Development Operations |
| Carlos L. del Rio | Senior Vice President, Cardiovascular Research & Translational Science |
| Vance Russell | Senior Vice President, Chemistry, Manufacturing & Controls (CMC) |
| Emil deGoma | Chief Medical Officer |
| Marc Evanchik | Chief Scientific Officer |
| Michele Anderson | Chief Development Officer |
| Tyler Chavez | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Chris Viehbacher | Chair of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 | +7.4% |
| Q2 2026 | Sep 8, 2026 · After close | −1.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (May 2026) | Technical | 16 slides | May 11, 2026 |
| Technical Presentation | Technical | 15 slides |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$439.9M in the latest tranche · US$18 a share · Goldman Sachs & Co. LLC +4 Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Stifel (co-lead), Cantor (co-lead) | Sep 8, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Aug 5, 2026.
- Price
- US$18.00 a share
- Shares offered
- 21,250,000 shares of common stock
- Offering size
- US$382.5 million
- Underwriters' option
- Up to 3,187,500 more shares
- Listing
- BRVE on the Nasdaq Global Market
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, Cantor · In the order on the cover
- Shares delivered
- On or about Aug 7, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 29, 2026 |
| Filed publicly | Jul 15, 2026 |
| Amended once | Jul 30, 2026 |
| Shares registered with an exchange | Aug 3, 2026 |
| Declared effective by the SEC | Aug 5, 2026 |
| Final prospectus, with the price | Aug 6, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 6, 2026 |
| CERT · Exchange's certificate of listing | Aug 6, 2026 |
| EFFECT · Notice that a registration is effective | Aug 5, 2026 |
| S-1MEF · Registration of more shares for the same offering | Aug 5, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 3, 2026 |
| S-1/A · Registration statement, amended | Jul 30, 2026 |
| S-1 · Registration statement | Jul 15, 2026 |
| DRS/A · Draft registration statement, amended | Jun 8, 2026 |
| DRS · Draft registration statement | Apr 29, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 6, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 |
|---|---|
| Revenue | 0 |
| Research and development | 1.49M |
| Selling, general and administrative | 3.02M |
| Operating income | -4.50M |
| Income before tax | -66.1M |
| Net income | -66.1M |
| Earnings per share, basic | -0.90 |
Balance sheet
| Line | FY2025 |
|---|---|
| Cash and equivalents | 89.2M |
| Current assets | 89.3M |
| Total assets | 89.3M |
| Accounts payable | 1.06M |
| Current liabilities | 5.24M |
| Total liabilities | 155.2M |
| Shareholders' equity | -65.9M |
| Shares outstanding | 73.2M |
Cash flow
| Line | FY2025 |
|---|---|
| Cash from operations | -2.01M |
| Capital spending | -33.6M |
| Free cash flow | -35.6M |
| Cash from financing | 124.7M |
| Change in cash | 89.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Sep 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | Sep 8, 2026 | Results | SEC |
All 53 filings
Cap table
Built by 6ix from Braveheart Bio, Inc.’s releases · as of Sep 8, 2026
- Common shares
- 90,038,969
- Fully diluted
- 90,038,969
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 90,038,969 | Sep 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 3, 2026 | 90,038,969 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christopher A. Viehbacher Other companies: Biogen Inc. (President and Chief Executive Officer · Since at least Nov 14, 2022); Axcella Health Inc (Director · May 8, 2019 – May 8, 2019 · Past) | Director · Since at least Aug 5, 2026 |
| James Paul Rickey Other companies: Alpine Immune Sciences Inc (See Remarks · Jul 24, 2017 – May 20, 2024 · Past); Immune Design Corp (VP, Finance and Administration · Jul 23, 2014 – Jan 7, 2015 · Past) | Chief Financial Officer · Since at least Aug 5, 2026 |
| Jason Coloma Other companies: Maze Therapeutics, Inc. (Chief Executive Officer · Since at least Jan 30, 2025); Corvus Pharmaceuticals, Inc. (SVP, Chief Business Officer · Jun 8, 2016 – Jun 8, 2016 · Past) | Director · Since at least Aug 5, 2026 |
| Erez Chimovits Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 28, 2026) | Director · Since at least Aug 7, 2026 |
| Jasper Bos Other companies: enGene Therapeutics Inc. (Director · Since at least Oct 31, 2023) | Director · Since at least Aug 5, 2026 |
| Travis Murdoch Other companies: Zymergen Inc (Director · Apr 21, 2021 – Oct 19, 2022 · Past) | CEO and President, Director · Since at least Aug 5, 2026 |
| Vineeta Agarwala Other companies: Tenet Healthcare Corporation (Director · Since at least Dec 11, 2023) | Director · Since at least Aug 7, 2026 |
| Brittany de Temple | Senior Vice President, Development Operations · Since at least Nov 4, 2026 |
| Carlos L. del Rio | Senior Vice President, Cardiovascular Research & Translational Science · Since at least Oct 30, 2026 |
| Chris Viehbacher | Chair of the Board · Since at least Aug 7, 2026 |
All 17 people
| Person | Seat |
|---|---|
| David I Malek | Director · Since at least Aug 5, 2026 |
| Emil deGoma | Chief Medical Officer · Since at least Nov 4, 2026 |
| Marc Evanchik | Chief Scientific Officer · Since at least Nov 4, 2026 |
| Michele Anderson | Chief Development Officer · Since at least Aug 5, 2026 |
| Paul Rickey | Chief Financial Officer · Since at least Nov 4, 2026 |
| Tyler Chavez | Chief Business Officer · Since at least Nov 4, 2026 |
| Vance Russell | Senior Vice President, Chemistry, Manufacturing & Controls (CMC) · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Braveheart Bio, Inc.